Aridis receives agreement from the european medicines agency (ema) on the clinical study design and a single confirmatory phase 3 study of ar-301

Los gatos, calif., july 17, 2023 (globe newswire) -- aridis pharmaceuticals, inc. (nasdaq: ards) today announced positive feedback from the european medicines agency (ema) on the company's proposed single confirmatory phase 3 study of investigational monoclonal antibody candidate ar-301, which is being developed as an adjunctive therapy in combination with standard of care (soc) antibiotics for the treatment of pneumonia caused by gram-positive bacteria staphylococcus aureus (s. aureus) in mechanically ventilated hospitalized patients.
ARDS Ratings Summary
ARDS Quant Ranking